·Basic Research··Current
Issue· ·Achieve· ·Search
Articles· ·Online Submission· ·About IJO·
Time-dependent matrix metalloproteinases and tissue inhibitor
of metalloproteinases expression change in fusarium
solani keratitis
Qian Li1, Xin-Rui
Gao2, Hong-Ping
Cui1, Li-Li Lang1, Xiu-Wen
Xie3, Qun Chen4
1Department of
Ophthalmology, Shanghai East Hospital, Tongji
University School of Medicine, Shanghai 200120,
China
2Department of
Ophthalmology, Shanghai Tenth People's Hospital, Tenth
People's Hospital of Tongji University, Shanghai 200072, China
3Department of
Ophthalmology, Changzhou Third People's Hospital, Changzhou 213001, Jiangsu
Province, China
4Department of
Ophthalmology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135,
China
Co-first authors: Qian
Li and Xin-Rui Gao
Correspondence to: Hong-Ping
Cui. Department of Ophthalmology, Shanghai East Hospital, Shanghai
200120, China. hpcui@vip.163.com
Received: 2015-02-04
Accepted: 2015-07-16
Abstract
AIM: To investigate matrix metalloproteinases (MMPs) and tissue
inhibitor of metalloproteinases (TIMPs) expression during the progress of fusarium
solani (F.solani) keratitis in a rat
model.
METHODS: A rat model of F.solani
keratitis was produced using corneal scarification and a hand-made contact
lens. MMPs and TIMPs expressiond were explored in this rat model of F.solani keratitis using real-time
polymerase chain reaction (PCR) and DIF. GM6001 (400 μmol/mL) was used to treat
infected corneas. The keratitis duration, amount and area of corneal
neovascularization (CNV) were evaluated.
RESULTS: MMP-3 expression was 66.3 times
higher in infected corneas compared to normal corneas. MMP-8, -9, and -13 expressions
were significantly upregulated in the mid-period of the infection, with
infected-to-normal ratios of 4.03, 39.86, and 5.94, respectively. MMP-2 and -7
expressions increased in the late period, with the infected-to-normal ratios of
5.94 and 16.22, respectively. TIMP-1 expression was
upregulated in the early period, and it was 43.17 times higher in infected
compared to normal corneas, but TIMP-2, -3, and -4 expressions were mildly
downregulated or unchanged. The results of DIF were consistent with the result
of real-time PCR. GM6001, a MMPs inhibitor, decreased the duration of F.solani infection and the amount and
area of CNV.
CONCLUSION: MMPs and TIMPs contributed into the progress of F.solani keratitis.
KEYWORDS: fungal keratitis; fusarium solani; metalloproteinases; tissue
inhibitors of metalloproteinases
DOI:10.18240/ijo.2016.04.06
Citation: Li Q, Gao XR, Cui HP, Lang LL, Xie XW, Chen Q. Time-dependent matrix
metalloproteinases and tissue inhibitor of metalloproteinases expression change
in fusarium solani keratitis. Int J Ophthalmol 2016;9(4):512-518
INTRODUCTION
Scarring of
the cornea resulting from suppurative keratitis is an important cause of
preventable blindness. In some developing countries in the tropics, corneal
infections are the second most common cause of blindness, after untreated
cataracts[1]. Suppurative
corneal ulcers may be caused by bacteria, fungi, and protozoa. However, fungal
keratitis has been recently found to play an important role. Fusarium solani (F.solani) is the most common fungal corneal isolate in China[2]. We have made a
experimental model of F.solani
keratitis in rats in our previous study, which is used in this study[3].
The main pathological features of
corneal infections are suppurative inflammation, histopathological changes and
changes in a variety of proteolytic enzymes that have a direct connection with
corneal tissue degradation in fugal keratitis. Matrix metalloproteinases (MMPs)
are a conserved family of zinc-dependent proteinases that act as both
regulators and effectors of many normal and pathological processes including
developmental tissue remodeling, wound healing, angiogenesis, inflammation, and
tumor progression[4].
Overexpression of MMPs has been correlated with pathologic conditions such as
corneal ulceration, epithelial ingrowth, keratoconus and other complications[5-7]. MMPs are aslo the
main enzymes that degrade the extracellular corneal matrix (ECM) that play a
critical rloe in the process of neovascularization[8], and these enzymes have been studied by many
scholars [9-11].
Tissue
inhibitors of matrix metalloproteinases (TIMPs) are also important in fugal
keratitis research[12].
The altered balance of MMPs and TIMPs triggered by inflammatory cytokines
enhance matrix degradation of the corneal stroma[13-15]. However, the role of MMPs and TIMPs in the
progress of fugal keratitis is unclear.
Yuan et al[16] investigated the expression of MMPs and TIMPs
during the inception and progression of experimental candida albicans keratitis, and this is a comprehensive study of
MMPS and TIMPs in one kind of fungal keratitis in recent research. Yuan et
al[16] found
transcriptional and translational levels of MMP-8, -9, -13, and TIMP-1 increase
during the early stages of C. albicans
keratitis, confirming findings for MMP-9 and TIMP-1 in other infectious
keratitis models and suggesting roles for MMP-8 and -13. We systematically
examined the expression patterns of 7 MMPs and 4 TIMPs in murine F.solani keratitis.
GM6001 (Iloasmtat,
Galardin) MMP inhibitor is a potent inhibitor of collagenase. It is a broad
spectrum inhibitor of MMPs for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 with Ki
of 0.4 nmol/L, 0.5 nmol/L, 27 nmol/L, 0.1 nmol/L, 0.2 nmol/L respectively.
GM6001 is widely used to inhibit MMPs in
vitro experiments and in animal models. In this study, GM6001,as a synthetic MMPs
inhibitor, was used to treat F.solani
keratitis in a rat model and to confirm the action of MMPs.
MATERIALS AND METHODS
Fungi F.solani strains were purchased
from the China General Microbiology Culture Collection Center (CGMCC), species
number 3.5840. The F.solani was
inoculated into potato dextrose agar solid medium for 7d at 24℃,
harvested in sterile phosphate buffered saline (PBS), and diluted with sterile
saline, to yield an inoculum with 1×108 CFU/mL.
Animals Normal adult Wistar rats, each
weighing 180 to 220 g [provided by the Department of Animal Science, Fudan
University, license number SCXK (Shanghai) 2002-0002]. The animals were
provided a standard diet and water ad libitum and housed in a
temperature (21℃-23℃) and humidity (45%-50%) controlled
room under a constant 12h light, 12h dark cycle. The protocols were approved by
the Animal Care and Use Committee of Tongji University and are in accordance
with the National Institutes of Health “Guide for the care and use of
laboratory animals” (NIH publication No. 85-23, revised 1996). All Wistar rats
were examined for eye disease using a slit lamp before surgery. Rats were
anesthetized intraperitoneally using rodent combination anesthesia, and both
corneas of each rat were scarified using a hypodermic needle to create a
superficial wound of intersecting marks in a grid pattern[15]. A 5 μL inoculum (1×108
CFU/mL) of F.solani was applied to
the right eye, while sterile PBS dilution buffer was applied to left eye as a
mock-infected control. A hand-made contact lens with a curvature of
approximately 3.13 mm was made from parafilm M filmand applied to each eye[3]. The eyelids were sutured
shut for one day. Rats were sacrificed on 1, 2, 3, 6, 10 and 14d post
inoculation (p.i.), and the eyes were enucleated for analysis.
Scoring Rats were scored daily for
up to 14d p.i. with the aid of a dissecting microscope and slit lamp[15]. Briefly, a grade of 0 to
4 was assigned to each of 3 criteria: area of corneal opacity, density of corneal
opacity, and corneal surface regularity, as previously described[15].
RNA
Extraction and Quantitative Real-time Polymerase Chain Reaction Corneas
were dissected from freshly enucleated eyes, and from the surrounding
conjunctiva, Tenon capsule, and uvea. Randomly grouped five-cornea pools were
prepared in triplicate from F.solani-infected
and mock-infected control animals at days 1, 2, 3, 6, 10 and 14 p.i., and from
normal unmanipulated rat corneas. Total RNA was immediately extracted (Triziol,
Invitrogene), and dissolved in RNase free water, separated using agarose gel
electrophoresis, and the rest was stored at -80℃ until use.
Total RNA, isolated from normal rat
corneas, F.solani-infected corneas
and mock-infected corneas on days 1, 2, 3, 6, 10 and 14 p.i., was quantified
spectroscopically at an absorption of 260 nm. The first-strand cDNA was
synthesized using 0.5 μg total RNA and a RT regent Kit (SYBR® PrimeScript RT
reagent Kit, Takara Biotechnology). Real-time polymerase chain reaction (PCR)
was performed using an assay with
primers specific for the various MMPs and TIMPs transcripts (Table 1). The
threshold cycle (Ct) for each target mRNA was normalized to β-actin mRNA.
Normalized Ct results were used to calculate gene expression levels, and the mean
results were used to determine the relative fold changes between experimental
groups.
Table 1 MMPs and TIMPs primers
Gene |
Genbank no. |
Primer |
Product |
MMP-2 |
NM_031054.2 |
FW: 5’-GTAAAGTATGGGAACGCTGATGGC-3’; RV: 5’-CTTCTCAAAGTTGTACGTGGTGGA-3’ |
135 bp |
MMP-3 |
NM_133523.2 |
FW: 5’-GTTCCTTGGGCTGAAGATGAC-3’; RV: 5’-TGGAAAGGTACTGAAGCCACC-3’ |
106 bp |
MMP-7 |
NM_012864.2 |
FW: 5’-GCAGACATCATAATTGGCTTCG-3’; RV: 5’-AGTCCTCACCATCCGTCCAG-3’ |
157 bp |
MMP-8 |
NM_022221.1 |
FW: 5’-ACTGGGCTCTAAGTGCCTATGAC-3’; RV: 5’-ATCTCCAGCATTGGTTGTTTACG-3’ |
147 bp |
MMP-9 |
NM_031055.1 |
FW: 5’-GGGCTTAGATCATTCTTCAGTG-3’; RV: 5’-GCCTTGGGTCAGGTTTAGAG-3’ |
137 bp |
MMP-10 |
NM_133514.1 |
FW: 5’-AGACAGGCACTTCTGGCGTAG-3’; RV: 5’-TCTTTGGGTAACCTGCTTGGA-3’ |
194 bp |
MMP-13 |
NM_133530.1 |
FW: 5’-CAAGCAGCTCCAAAGGCTACAAC-3’; RV: 5’-GGAAACATCAGGGCTCCAGGGTC-3’ |
103 bp |
TIMP-1 |
NM_053819.1 |
FW: 5’-GCCTCTGGCATCCTCTTGTTG-3’; RV: 5’-CATAACGCTGGTATAAGGTGGTC-3’ |
163 bp |
TIMP-2 |
NM_021989.2 |
FW: 5’-ACACGCTTAGCATCACCCAGAA-3’; RV: 5’-CAGTCCATCCAGAGGCACTCAT-3’ |
130 bp |
TIMP-3 |
NM_012886.2 |
FW: 5’-GCCGTTTATGGAGTTGATTTGG-3’; RV: 5’-AGTGCGGTCTCATTCTTTCTGG-3’ |
130 bp |
TIMP-4 |
NM_001109393.1 |
FW: 5’-CAGTATGTCTACACGCCATTTGA-3’; RV: 5’-TCTGGTGGTAGTGATGATTCAGG-3’ |
193 bp |
β-actin |
NM-031144 |
FW: 5’-CGTAAAGACCTCTATGCCAACA-3’; RV: 5’-TAGGAGCCAGGGCAGTAATC-3’ |
100 bp |
Direct
Immunofluorescence Corneas from infected eyes
and mock-infected eyes on 1, 2, 3, 6, 10, and 14d p.i., and the corneas from
the 5 normal rats were fixed in 4% paraformaldehyde, embedded in paraffin, and
serially sectioned at a thickness of 4 μm. The sections were deparaffinized,
and blocked with 10% normal donkey serum in PBS for 1h to decrease nonspecific
binding. The following primary antibodies were diluted 1:100, applied to the
blocked sections, and incubated overnight at 4℃: MMP-2, -9 (AB19016, AB19167,
Millipore), MMP-3, -7, -8, and TIMP-1, -2, -3, -4 (sc-6839, sc-26680, sc-8848,
sc-5538, Santa Cruz Biotechnology).
GM6001
Treatment With
an initial concentration of 2.5 mmol/mL, GM6001 (Chemicon), a specfic MMPs
inhibitor, was diluted into a concentration of 400 µg mol/mL using PBS buffer,
and was kept at pH 6.5 to 7.5, stored in small quantities at 4℃. Rats (n=20) were inoculated with F.solani,
and randomly divided into a GM6001 group (400
µmol/mL GM6001) or a saline group (0.9% normal saline). At 2d p.i., rats were
given eye drops (25 μL, 5 times per day between 8:00 and 16:00). All
experimental eyes were coated with erythromycin eye ointment every night to
prevent bacterial infection, and an tropicamide drop was administered to avoid
closure of the pupillary membrane.
The
duration of infection, and the amount and area of corneal neovascularization (CNV) were used to evaluate the therapeutic
efficacy of GM6001. Corneas from the experimental eye were placed into
paraffin, and dyed using hematoxylin-eosin (HE) stain. Three random slices of
each specimen were assessed, and six random high-power field (HPF; ×400) areas
from each slice were assessed. The amount of CNVs within the full field,
excluding the pipe diameter, was calculated. The CNV area was calculated using
the following equation: area (mm2)=0.2×π×maximal×vessel length
(mm)×time (h) of CNV involving the cornea[17].
Statistical Analysis Data are
expressed as the mean±SD. Score were evaluated for statistical significance using a
Kruskal-Wallis 1-way analysis of variance on ranks. Pairwise multiple
comparison procedures included Dunn’s method and the Tukey test. For kinetic analysis of MMPs and TIMPs
transcriptional levels, the mean results were compared using ANOVA with the
Holm-Sidak method for pairwise multiple comparison procedures. Corneal lesion
scoring, the amount and area of CNV and the CNV group were assessed using a
paired-sample t-test. P<0.05 was considered to be
statistically significant. Data were analyzed using SPSS 12.0 (SPSS Inc, USA).
RESULTS
Duration of F.solani Keratitis All eyes inoculated with F.solani developed clinical signs of
keratitis. The infection was present for 14d and the infected corneas were
observed using a slit lamp. There was no inflammation in eyes from
mock-infected controls. Histopathologic evaluation of infected eyes revealed
partial loss of epithelial integrity, acute inflammatory cells invading the
stroma, and PAS staining showed hyphae invading into the mid to deep stroma.
Clinical scoring (Figure 1) indicated that the infection was divided into an
early period (1d p.i.), a mid-period (2-5d p.i.) and a late period (6-14d p.i.).
There were significant differences between control corneas, corneas at 6d p.i.,
and corneas observed on other days p.i. (P<0.05).
Figure 1 Clinical
evaluation of F.solani keratitis The
disease course was divided into an early period (1d p.i.), a mid-period (2-5d
p.i.) and a late period (6-14d p.i.). Each point represents the mean score for
each day.
Matrix
Metalloproteinases and Tissue Inhibitor of Metalloproteinases Gene
Expression MMPs
and TIMPs transcript levels in the five F.solani-infected
cornea pools and in the five mock-infected cornea pools were assessed using
real-time PCR, and 7 members of MMPs and 4 members of TIMPs were detected.
Table 2 and
Figure 2 shows the MMPs and TIMPs genes
expression in the infected corneas and mock-infected corneas. The gene
expression was considered to be normal before infection or mock-infection.
MMP-7, -8, -10, -13 were not expressed in the normal cornea. MMP-3 expression
was 66.3 times higher in the infected cornea compared to the normal cornea.
MMP-8, -9, -13 expression was significantly upregulated in the mid-period
(infected-to-normal ratios of 4.03, 39.86, and 5.94, respectively). MMP-2, -7
expression was increased in the late period (infected-to-normal ratios of 5.94
and 16.22, respectively). TIMP-1 was upregulated in the early period, and was
43.17 times higher in infected compared to normal corneas, but TIMP-2, -3, -4
expressions were mildly downregulated or unchanged.
Table 2 Gene expression levels in
infected and mock-infected corneas
Gene |
Group |
Pre-infection expression level |
Gene expression levels |
|||||
Day 1 |
Day 2 |
Day 3 |
Day 6 |
Day 10 |
Day 14 |
|||
MMP-2 |
Infected |
1 |
1.83±0.25 |
2.54±0.55 |
4.19±0.46 |
5.94±0.24 |
11.61±1.75 |
3.09±0.45 |
|
Mock |
1 |
1.47±0.01 |
1.22±0.06 |
0.20±0.05 |
0.13±0.07 |
0.98±0.07 |
1.07±0.08 |
MMP-3 |
Infected |
1 |
66.30±2.30 |
26.61±3.67 |
17.63±0.12 |
10.08±0.63 |
6.73±0.19 |
14.23±0.39 |
|
Mock |
1 |
14.66±1.12 |
3.40± 0.33 |
1.39±0.11 |
1.00±0.03 |
1.07±0.01 |
1.04±0.01 |
MMP-7 |
Infected |
-- |
1 |
3.81±0.03 |
5.21±0.07 |
3.66±0.48 |
8.28±1.37 |
16.22±0.22 |
|
Mock |
-- |
1 |
2.01±0.04 |
0.96±0.07 |
0.31±0.01 |
0.20±0.05 |
0.15±0.04 |
MMP-8 |
Infected |
-- |
1 |
1.72±0.14 |
4.03±0.03 |
1.15±0.29 |
1.09±0.02 |
0.50±0.06 |
|
Mock |
-- |
1 |
0.49±0.01 |
0.41±0.05 |
0.40±0.05 |
0.40±0.04 |
0.39±0.05 |
MMP-9 |
Infected |
1 |
22.63±2.65 |
29.24±0.20 |
39.86±3.86 |
20.33±2.93 |
5.10±0.14 |
1.28±0.04 |
|
Mock |
1 |
29.58±2.86 |
11.79±2.66 |
5.37±0.52 |
1.27±0.17 |
1.22±0.05 |
1.01±0.01 |
MMP-10 |
Infected |
-- |
1 |
0.93±0.09 |
1.18±0.07 |
0.16±0.02 |
0.24±0.02 |
0.82±0.04 |
|
Mock |
-- |
1 |
0.58±0.06 |
0.85±0.01 |
0.36±0.03 |
0.28±0.01 |
0.23±0.05 |
MMP-13 |
Infected |
-- |
1 |
2.95±0.63 |
5.94±0.74 |
1.91±0.45 |
0.06±0.02 |
0.02±0.01 |
|
Mock |
-- |
1 |
0.48±0.02 |
0.26±0.02 |
0.18±0.01 |
0.19±0.02 |
0.18±0.01 |
TIMP-1 |
Infected |
1 |
43.17±2.39 |
14.88±3.25 |
8.91±0.80 |
7.56±1.19 |
3.13±0.47 |
0.64±0.11 |
|
Mock |
1 |
13.20±1.72 |
2.81±0.34 |
1.98±0.02 |
0.95±0.20 |
0.74±0.17 |
0.57±0.02 |
TIMP-2 |
Infected |
1 |
0.49±0.03 |
0.48±0.05 |
0.62±0.09 |
1.19±0.11 |
1.15±0.05 |
1.38±0.23 |
|
Mock |
1 |
0.54±0.12 |
0.90±0.18 |
1.07±0.18 |
1.24±0.21 |
1.41±0.17 |
1.47±0.12 |
TIMP-3 |
Infected |
1 |
0.74±0.16 |
1.25±0.07 |
0.54±0.10 |
0.29±0.06 |
1.01±0.09 |
0.81±0.15 |
|
Mock |
1 |
0.89±0.09 |
1.02±0.19 |
1.02±0.21 |
1.05±0.07 |
1.08±0.13 |
1.12±0.14 |
TIMP-4 |
Infected |
1 |
0.11±0.02 |
0.17±0.01 |
0.15±0.03 |
014±0.03 |
0.61±0.03 |
0.93±0.01 |
|
Mock |
1 |
0.44±0.02 |
0.63±0.05 |
0.83±0.08 |
0.85±0.03 |
0.99±0.01 |
0.99±0.02 |
Five cornea
pools (each with triplicate samples) of normal, mock-infected, or fungal F.solani-infected corneas at 1, 2, 3, 6,
10, 14d p.i. were assessed using real-time PCR and reported as the mean Ct
number±SD (normalized to β-actin). --: No expression.
Figure 2 Differential gene expression ratios of MMPs and TIMPs in F.solani keratitis compared to control
(mock-infected) and normal rat corneas
Total MMPs and TIMPs mRNA expression compared to controls and normal corneas was quantified using
real-time PCR, with Ct values normalized to β-actin. A: MMPs ratios of infected compared to mock-infected
corneas; B: TIMPs ratios of infected compared to mock-infected corneas; C: MMPs
ratios of infected compared to normal corneas; D: TIMPs ratios of infected
compared to normal corneas.
Matrix
Metalloproteinases and Tissue Inhibitor of Metalloproteinases Protein
Expression Protein expression was
determined using DIF staining, and these results were consistent with the
transcript levels measured using real-time PCR. MMP-8, -9 were expressed during
the mid-period, MMP-2, -7 were expressed during the late period, and TIMP-1 was
expressed 1d p.i. (Figure 3).
Figure 3 DIF staining of MMP-2, -3,-7, -8, -9 and TIMP-1 in infected and
mock-infected corneas DAPI (blue)-nuclei, DIF (green)-MMPs and TIMPs.
Efficacy of
GM6001 Treatment GM6001, a MMPs specfic
inhibitor, treatment decreased the
infection duration to 11.50±0.71d compared to 14.20±0.92d in
rats that received saline drops. The amount and area of CNV were significantly reduced in
the infected group that received GM6001 compared to the infected group that
received saline (Table 3, Figures
4, 5).
Table 3
GM6001 efficacy and area of CNV
Groups |
Duration of infection (d) |
Amount of CNV (×400) |
Area of CNV (mm2) |
Saline |
14.20±0.92 |
8.90±1.10 |
38.01±1.74 |
GM6001 |
11.50±0.71 |
8.10±0.74 |
32.51±1.51 |
P |
<0.001 |
0.087 |
<0.001 |
Figure 4 CNV at day 14 p.i.
Figure 5 CNV
stained using HE (×100).
DISCUSSION
Leukocyte-derived MMPs that are involved in fungal keratitis include
collagenase (MMP-8), gelatinase (MMP-9), stromeylsin (MMP-10), and elastase
(MMP-12), which are released from polymorphonuclear leukocytes (PMNs) or
macrophages soon after microbial inoculation[16]. Our study confirms that MMP-8 and MMP-9 expression
increased during F.solani keratitis.
MMP-8 and MMP-9 expression is upregulated in the early-and mid-period of the
infection at the RNA level, and DIF showed their expression in the corneal
epithelium. Previous studies found that MMP-8, -9 expression was significantly
increased in the tear ducts, corneal tissue and serum samples taken from eyes
with fungal keratitis[12], the mRNA levels for MMP-9, -10 were significantly
up-regulated in the migrating corneal epithelium[18]. Infiltrating PMNs in the cornea with fungal
keratitis contributed to the increased MMP-8 and MMP-9 activities, thereby
enhancing tissue destruction and derangement. More expression of MMP-9 is found
in mock-infected cornea than F.solani
infected cornea in 1d, MMP-9 increases immediately after superficial corneal
wounding[19] and fungal
infection perpetuates its upregulation.
MMP-2, -7
play an important role during the corneal repair process, remodeling and
angiogenesis. MMP-2 expression was increased during corneal neovascularization
and that this neovascularization was mainly localized to the cells infiltrating
areas of new vessel formation[20].
In addition, MMP-2 may appear later during the wound-healing process, MMP-2 is
important for ECM remodeling in corneal ulcers[21], and MMP‑2 is important in the development of
corneal stromal
ulcers[22]. MMP-7 was
found to prevent CNV formation, basal epithelial cells express MMP-7 during the
migration proliferation phase of corneal wound healing after excimer
keratectomy[23]. We
found, using real-time PCR, that the expression of MMP-2, -7 is upregulated in
the late period of F.solani
infection, and DIF results are consistent with the real-time PCR findings,
which suggests that MMP-2, -7 play a role in the recovery process and ECM
remodeling in F.solani keratitis.
Stromelysin-1 (MMP-3) degrades proteoglycan core proteins, laminin,
fibronectin, elastin, gelatin, and collagen types III, IV, V, VII, and IX[24]. The degradation of the
epithelial basement membrane during keratolysis could also be caused by MMP-3[25]. MMP-3 can be
upregulated by IL-1β and TNF-α in corneal epithelial cells[26], and secreted by epithelial cells in the newly
formed multi-layer or on the bottom of the deep stromal fibroblasts[27]. We found that MMP-3
expression was upregulated in the early period of F.solani keratitis, MMP-3 expression may be an early corneal
response to corneal inflammation, MMP-3 increased significantly in 1d both in
mock-infected cornear and infected conear. In addition, MMP-3 plays an
important role in epithelial basement membrane and extracellular matrix
remodeling[28], and this
may explain why MMP-3 expression increased in the late period in F.solani keratitis.
We found that there was no MMP-13 expression in the normal rat cornea,
which is consistent with results presented by Ye et al[29]. By digesting collagen
and proteoglycan, MMP-13 may be involved in reparative processes of ulcerative
keratomycosis[16]. In our
study, we found that MMP-13 expression increased in the mid-period, and MMP-13
mRNA was detected in epithelial cells of wounded corneas, but not in normal
controls, Zou et al[30] found more MMP-13 at
day 3 post infection, but less MMP-13, at later time points in experimental
Candida albicans keratitis. MMP-13 may play an important role in the gelatinase
B-associated proteolytic cascade that allows rapid turnover of the ECM
components during corneal wound healing[28].
It’s
worth mentioning that MMP-13 may activate MMP-9 in the corneal wound[28], in our study, the
change trend of MMP-9 was consistent with MMP-13. These results of divergence
expression of MMPs family suggested difference function in keratitis.
TIMPs are the major endogenous regulators of MMPs activity in tissues.
Adequate TIMPs expression reduces damage to the corneal stroma during
infection. TIMP-1 was upregulated during F.solani
keratitis, and TIMP-1 expression was amplified by fungal infection within 1d to
43.17 times that of the normal cornea, and 3.32 times that of the control
(mock-infected) cornea. This indicates that early in the course of the disease,
MMPs expression is elevated and TIMP-1 increases to antagonize the elevated
MMPs expression. As the disease progresses and healing eventually occurs,
TIMP-1 expression begins to decline. Though increased by corneal trauma, the
expression of TIMP-1 is amplified by fungal infection within 2d to >5 times
that of scarified controls. TIMP-2, -3, -4 expression, on the other hand, was
mildly downregulated or unchanged. There may be a network adjustment mechanism
between MMPs and TIMPs during F.solani
keratitis. Corneal homeostasis depends on interactions between MMPs and TIMPs,
an important mechanism for the regulation of the MMPs activity is via binding to a family of homologous
proteins referred to as TIMPs[31],
positive correlation was showed between MMP-9 and TIMP-1 in inflammatory cell
immunoreactivity in fungal affected Paraffin-embedded equine corneal samples[32], but the mechanism is
not known and requires further research. The ratio of MMPs to TIMPs may be
important to determine the course of F.solani
keratitis.
In addition, there were obvious differences in gene expression of MMPs
and TIMPs between mock-infected (control) and normal rat corneas, which proved
that the expression of MMPs and TIMPs were changed with corneal trauma.
GM6001 is a synthetic MMPs inhibitor that inhibits MMPs activity through
recognition of the MMPs substrate recognition site. GM6001 is considered to be
the most powerful synthetic MMPs inhibitor. GM6001 (400 μmol/mL) was used to
treat F.solani keratitis, and we
found that GM6001 can shorten the duration of infection and decrease the amount
and area of CNV, and these results can confirm the action of MMPs.
In conclusion, this study showed the
time-dependent expression of MMPs and TIMPs in a rat F.solani keratitis model. We have shown that tissue and
inflammatory responses induced upregulation of some MMPs after infection of the
cornea with F.solani. MMP-3, -7, -8, -9
may contribute to ulcerative keratitis and facilitate fungal growth and
extension, and MMP-2, -3 and TIMPs may play an important role in corneal
healing. A MMPs inhibitor could be a potential candidate to treat F.solani keratitis. This study didn’t
research molecular mechanism of the changes, which is our further work.
ACKNOWLEDGEMENTS
Foundation:
Supported by Tongji University, Shanghai, China (No.
2012KJ042).
Conflicts of Interest: Li Q, None; Gao XR, None; Cui HP, None; Lang LL,
None; Xie XW, None; Chen Q, None.
REFERENCES [Top]
1 Leck AK, Thomas PA, Hagan M, Kaliamurthy J, Ackuaku E, John M,
Newman MJ, Codjoe FS, Opintan JA, Kalavathy CM, Essuman V, Jesudasan CA,
Johnson GJ. Aetiology of suppurative corneal ulcers in Ghana and south India,
and epidemiology of fungal keratitis. Br
J Ophthalmol 2002;86(11):1211-1215. [CrossRef]
2 Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in
north China. Ophthalmology 2006;113(11):1943-1948.
[CrossRef]
[PubMed]
3 Zhu JL, Gao XR, Cui HP, Lang LL, Li Q, Liao X. Experimental
model of Fusarium solani keratitis in rats. Int
J Ophthalmol 2011;4(4):371-376. [PMC
free article] [PubMed]
4 Nagase H,Visse R, Murphy G. Structure and function of matrix
metalloproteinases and TIMPs. Cardiovasc
Res 2006;69(3):562-573. [CrossRef]
[PubMed]
5 Brejchova K, Liskova P, Hrdlickova E, Filipec M, Jirsova K.
Matrix metalloproteinases in recurrent corneal melting associated with primary
Sjörgen’s syndrome. Mol Vis 2009;15:2364-2372. [PMC
free article] [PubMed]
6 Mackiewicz Z, Maatta M, Stenman M, Konttinen L, Tervo T,
Konttinen YT. Collagenolytic proteinases in keratoconus. Cornea 2006;25(5):603-610. [CrossRef]
[PubMed]
7 Fournié PR, Gordon GM, Dawson DG, Malecaze FJ, Edelhauser HF,
Fini ME. Correlation between epithelial ingrowth and basement membrane remodeling
in human corneas after laser-assisted in
situ keratomileusis. Arch Ophthalmol 2010;128(4):426-436. [CrossRef] [PubMed]
8 Lafleur MA, Handsley MM, Edwards DR. Metalloproteinases and
their inhibitors in angiogenesis. Expert
Rev Mol Med 2003;5(23):1-39. [CrossRef]
9 Mitchell BM, Wu TG, Chong EM, Pate JC, Wilhelmus KR. Expression
of matrix metalloproteinases 2 and 9 in experimental corneal injury and fungal
keratitis. Cornea 2007;26(5):589-593.
[PubMed]
10 Dong X, Shi W, Zeng Q, Xie L. Roles of adherence and matrix
metalloproteinases in growth patterns of fungal pathogens in cornea. Curr Eye Res 2005;30(8):613-620. [CrossRef] [PubMed]
11 Gopinathan U, Ramakrishna T, Willcox M, Rao CM, Balasubramanian
D, Kulkarni A, Vemuganti GK, Rao GN. Enzymatic, clinical and histologic
evaluation of corneal tissues in experimental fungal keratitis in rabbits. Exp Eye Res 2001;72(4):433-442. [CrossRef] [PubMed]
12 Rohini G, Murugeswari P, Prajna NV, Lalitha P, Muthukkaruppan
V. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of
metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis. Cornea 2007;26(2):207-211. [CrossRef]
13 Sakimoto T, Ohnishi T, Ishimori A. Simultaneous study of matrix
metalloproteinases, proinflammatory cytokines, and soluble cytokine receptors
in the tears of noninfectious corneal ulcer patients. Graefes Arch Clin Exp Ophthalmol 2014; 252(9):1451-1456. [CrossRef] [PubMed]
14 Lopilly Park HY, Kim JH, Lee KM, Park CK. Effect of prostaglandin
analogues on tear proteomics and expression of cytokines and matrix
metalloproteinases in the conjunctiva and cornea. Experimental Eye Research 2012;94(1):13-21. [CrossRef] [PubMed]
15 Wu TG, Keasler VV, Mitchell BM, Wilhelmus KR. Immunosuppression
affects the severity of experimental Fusarium solani keratitis. J Infect Dis 2004;190(1):192-198. [CrossRef] [PubMed]
16 Yuan X, Mitchell BM, Wilhelmus KR. Expression of matrix
metalloproteinases during experimental Candida albicans keratitis. Invest Ophthalmol Vis Sci 2009;50(2):737-742.
[CrossRef] [PubMed] [PMC
free article]
17 Kato T, Kure T, Chang JH, Gabison EE, Itoh T, Itohara S, Azar
DT. Diminished corneal angiogenesis in gelatinase A-deficient mice. FEBS Lett 2001;508(2):187-190. [CrossRef]
18 Gordon GM, Austin JS, Sklar AL, Feuer WJ, Lagier AJ, Fini ME.
Comprehensive gene expression profiling and functional analysis of matrix
metalloproteinases and TIMPs, and identification of ADAM-10 gene expression, in
a corneal model of epithelial resurfacing. J
Cell Physiol 2011;226(6):1461-1470. [CrossRef] [PubMed]
19 Carter RT, Kambampati R, Murphy CJ, Bentley E. Expression of
matrix metalloproteinase 2 and 9 in experimentally wounded canine corneas and
spontaneous chronic corneal epithelial defects. Cornea 2007;26(10):1213-1219. [CrossRef] [PubMed]
20 Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B.
Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial
growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70(4):419-428. [CrossRef] [PubMed]
21 Xue ML, Wakefield D, Willcox MD, Lloyd AR, Di Girolamo N, Cole
N, Thakur A. Regulation of MMPs and TIMPs by IL-1beta during corneal ulceration
and infection. Invest Ophthalmol Vis Sci 2003;44(5):2020-2025.
[CrossRef]
22 Cao T, Xing Y, Yang Y, Mei H. Correlation between matrix
metalloproteinase expression and activation of the focal adhesion kinase
signaling pathway in herpes stromal keratitis. Experimental and Therapeutic medicine 2014;7(1):280-286. [PubMed]
23 Lu PC, Ye H, Maeda M, Azar DT. Immunolocalization and gene
expression of matrilysin during corneal wound healing. Invest Ophthalmol Vis Sci 1999;40(1):20-27. [PubMed]
24 Murphy G, Docherty AJ. The matrix metalloproteinases and their
inhibitors. Am J Respir Cell Mol Biol 1992;7(2):120-125.
[CrossRef] [PubMed]
25 Brejchova K, Liskova P, Cejkova J, Jirsova K. Role of matrix
metalloproteinases in recurrent corneal melting. Exp Eye Res 2010;90(5):583-590. [CrossRef] [PubMed]
26 Li DQ, Shang TY, Kim HS, Solomon A, Lokeshwar BL, Pflugfelder
SC. Regulated expression of collagenases MMP-1,-8, and-13 and stromelysins
MMP-3,-10, and-11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003;44(7):2928-2936. [CrossRef]
27 Rosenblatt M, Yeh SI,
Chang JH, Azar D. Gene transfer of matrix melloproteinase-7 (MMP-7) to corneal
cell lines. Invest Ophthalmol Vis Sci 2004;45:4821.
28 Daniels JT, Geerling G, Alexander RA, Murphy G, Khaw PT,
Saarialho-Kere U. Temporal and spatial expression of matrix metalloproteinases
during wound healing of human corneal tissue. Exp Eye Res 2003;77(6):653-664. [CrossRef]
29 Ye HQ, Maeda M, Yu FS, Azar DT. Differential expression of
MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat
corneas. Invest Ophthalmol Vis Sci 2000;41(10):2894-2899. [PubMed]
30 Zou Y, Zhang H, Li H, Chen H, Song W, Wang Y. Strain-dependent
production of interleukin-17/interferon-γ and matrix remodeling-associated
genes in experimental Candida albicans keratitis. Mol Vis 2012;18:1215-1225.
[PMC
free article] [PubMed]
31 Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of
metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477(1-2):267-283. [CrossRef]
32 Boveland SD, Moore PA, Mysore J, Krunkosky TM, Dietrich UM,
Jarrett C, Paige Carmichael K. Immunohistochemical study of matrix
metalloproteinases-2 and-9, macrophage inflammatory protein-2 and tissue
inhibitors of matrix metalloproteinases-1 and-2 in normal, purulonecrotic and
fungal infected equine corneas. Vet
Ophthalmol 2010;13(2):81-90. [CrossRef]
[PubMed]
[Top]